A new treatment for lymph nodes that maintain fertility

A recent international study revealed that people with young Hodgkin -Lymphoma are advanced Hodgkin. They have a better chance of retaining their fertility and having children after recovering from the disease, thanks to a new chemotherapy protocol known as BRCADD. The new therapeutic protocol consists of a group of cancer medication, but one of the most important features is that it replaces some old, very toxic drugs with newer and less harmful medicine for the lungs and sex hormones. The study showed that patients treated with this system have higher opportunities to restore reproductive functions to recovery, especially men, everything without the effect of treatment in elimination of cancer. Lymphomatic cancer has always been the classic lymph nodes known as ‘Hodgkin’, usually affecting young people in the prime of life, and intense treatments, despite their high effectiveness to eliminate the disease, posed a great danger with permanent infection or poor fertility, and it affected the quality of the survivors and their desire to have children. Secondary analysis was performed within the clinical HD21 experience, which includes 233 centers in nine countries, and is compared between EBeacopp and BRCADD for newly diagnosed patients with lymphoma “Hodgkin” Advanced Classic. The EBeacopp and BRCADD system is one of the most important chemotherapy systems used to treat advanced cases of Hodgkin lymphoma, but between them are fundamental differences that affect the patient’s life directly after treatment, especially with regard to fertility and side effects. The traditional system EBeacopp is very effective in controlling the disease, but it consists of a group of strong and toxic drugs, including a drug known for the severe fertility effect called ‘brocar basin’, which can cause permanent damage to the gonades, especially in men, and this system contains another medicine known as the negative affects. On the other hand, the new BRCADD system is an attempt to reduce this damage without affecting the effectiveness of treatment, as the most toxic drugs have been replaced by less harmful medicine, such as replacing ‘brocar basin’ with ‘dacobacin’, which is an effective drug against cancer, but its effect on fertility is much lower. Brcadd also depends on a modern -focused medicine that helps to accurately target cancer cells, reducing the negative effect on the rest of the body’s tissue. The results of the study published in the journal “Lancet Unkology” states that the rate of recovery of the ovarian in women after 4 years of treatment with BRCADD amounts to an incredible percentage of 95.3%, compared to only 73.3% in the Ebeacop group. For men, the differences were clearer, as the BRCADD group recorded a rate of recovery from the gonad glands after 4 years with 85.6%, compared to only 39.7% in the Ebeacop group. Lymphomatic cancer is a type of cancer that affects the lymphatic system, which is part of the immune system responsible for infection control. It is characterized by the presence of abnormal cells known as ‘Red-Sterinberg cells’, which is a distinctive sign of this type of cancer. It often starts in the lymph nodes, such as in the neck, under the armpit or in the chest, and can gradually spread to other body parts. It usually affects young people between 15 and 35 years old, but it can also affect the elderly. Its common symptoms include painless inflammation in the lymph nodes, severe night sweats, weight loss without reason, regular fever, annoying itching and general fatigue. It is considered a very restored species, especially if it is detected early and the appropriate treatment begins. It is usually treated with chemotherapy and sometimes with radiotherapy. Fertilizer hormones were the levels of hormones that indicate fertility, such as the AMH hormone in women and the inhibin B -Mans in men, are usually higher in the group that received Brcadd treatment. The benefits were not limited to restoring the functions of the gonades, but also expanded to the actual results associated with birth; After five years of treatment, the parental rates were at least one child, much higher in men who received Brcadd (9.3%), compared to those who received Ebeacop (3.3%), confirming the positive impact on male fertility. While maternity rates were higher in the BRCADD group (19.3%) compared to Ebeacopp (17.1%), the difference was not statistically in women, but the difference still indicates a positive direction. Generally, 92 cases of pregnancy between patients and 36 pregnancy cases were reported between male patients partners, and these cases led to 108 births, of which 59 are in the Brcadd and 40 in the Ebeacopp group. The remarkable improvement in the preservation of fertility after the treatment of Hodgkin is due to an important adjustment in the composition of the new BRCADD treatment, as the drug “brocar basin” is known for its harmful and permanent effect on the gonades was replaced by the “Dakarbazine”, which has similar effectiveness against cancer cells, but a lower toker. reproductive system has. The change has come as part of a strategy aimed at reducing the side effects of chemotherapy, without compromising the ability to control the crop. The results of the study indicate that BRCADD achieves a high therapeutic effectiveness, with a clear reduction in the risk of fertility damage, especially in young patients who want children in the future. This study is the first detailed analysis that shows how the new treatment can maintain the function of the gonades, compared to the previous standard protocol, which increases the position of BRCADD as an advanced therapeutic option observed for the quality of life. These results highlight the importance of providing the BRCADD system as a first treatment line for the advanced classic lymphoma “Hodgkin”, especially for patients planning to have children, and emphasizes the need to continue to judge the functions of the sexual glands in the clinical trials of new cancer treatment, to give a comprehensive the life of patients. The researchers say that doctors and patients, thanks to this study, have a safer and more effective therapeutic choice, which combines the elimination of the disease and the preservation of the dream of fatherhood and motherhood.